Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of ritlecitinib in severe alopecia areata (China)
ChiCTR2500095989Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Xiangya Hospital, Central South University. Primary endpoints: Severity of hair loss and Pattern of administration of ritlecitinib. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ChiCTR2500095989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095989.